• It has been recognized for decades that neurons in the

  2023-09-14

  

  It has been recognized for decades that neurons in the mammalian central nervous system may release both a fast-acting, typically amino acid derived neurotransmitter such as glutamate or GABA, and a second peptidergic neuromodulatory molecule such as neuropeptide Y, substance P, or cholecystokinin.

• Recently biosensors based on enzyme mimicking

  2023-09-14

  

  Recently, biosensors based on enzyme-mimicking organic-inorganic hybrid nanomaterials such as protein or DNA-Cu nanoflowers (Batule et al., 2015, Park et al., 2017), Fe-aminoclay (Lee et al., 2013), and MOFs (Ai et al., 2013, Dong et al., 2015, Feng et al., 2012, Liu et al., 2013, Qin et al., 2013,

• Molecular docking simulations were carried out for ligands

  2023-09-14

  

  Molecular docking simulations were carried out for ligands – in the ACE crystal structure (1O86) and DPP4 crystal structure (2G5P). Comparison of the binding mode of – () with enalaprilat (a) in ACE shows that the phenethyl group (–, enalaprilat) occupies the S1 pocket and the adjacent carboxylic a2

• ACE inhibition is often thought to play a central role

  2023-09-14

  

  ACE inhibition is often thought to play a central role in the mechanisms of blood pressure reduction in vivo, and most ACE inhibitory (ACEi) peptides were characterized based on in vitro ACE inhibition. A relationship between in vitro ACE inhibition and antihypertensive activity, however, is not app

• The discovery of acetylsalicylic acid aspirin in paved

  2023-09-14

  

  The discovery of acetylsalicylic UCF 101 (aspirin) in 1897 paved the way for the development of classical NSAIDs as first-line therapeutics for anti-inflammatory, anti-pyretic and analgesic therapy. Large efforts have been made in the following decades to improve the efficacy and in particular safe

• hydroxydopamine OHDA is a selective catecholaminergic neurot

  2023-09-14

  

  6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin mainly used to generate lesions in the nigrostriatal pathway in rats (Ungerstedt, 1968). The most common use of 6-OHDA is via unilateral injection into the rat medial forebrain bundle (MFB). DA depletion, nigral DA cell loss, and

• br Conflicts of interest br Introduction Phosphatidic acid p

  2023-09-14

  

  Conflicts of interest Introduction Phosphatidic CRA-024781 phosphatase (PAP) enzymes are responsible for catalyzing the reaction that dephosphorylates phosphatidic acid (PA), which in turn produces diacylglycerol (DAG) and a phosphate group during phospholipid regulation (Fig. 1A) [1]. Subseq

• In this study we observed the ATPase activity of RaGroEL

  2023-09-14

  

  In this study, we observed the ATPase activity of RaGroEL at various temperatures and metal ions conditions and the role of GroES in the ATPase activity of RaGroEL. Furthermore, we quantified the expression of groEL genes under different abiotic stresses, including temperature, pH, salt and oxygen s

• br Acknowledgments This work was supported by

  2023-09-14

  

  Acknowledgments This work was supported by the Swiss National Science Foundation. 15-Lipoxygenase 1 (15-LOX-1) is a nonheme, iron-containing enzyme predominantly expressed in reticulocytes, eosinophils, macrophages, mast cells, and bronchial epithelial cells . 15-LOX-1 is a key enzyme involved

• br Introduction Lipoxygenases LOXs are a heterogeneous famil

  2023-09-14

  

  Introduction Lipoxygenases (LOXs) are a heterogeneous family of enzymes that catalyze the peroxidation of polyunsaturated fatty acids (PUFAs). By oxidizing free PUFAs, they were shown to contribute to the generation of various bioactive lipid mediators. However, LOX-mediated oxidation of PUFAs es

• In order to determine whether the faster

  2023-09-14

  

  In order to determine whether the faster Rh2-induced apoptosis is specific of cholesterol depletion, we determined the cytotoxic effect of Rh2 in Dyngo-4a depleted or not in sphingomyelin, another abundant plasma membrane lipid exhibiting enrichment in lipid rafts. We showed that, in contrast to cho

• APJ receptor expression is altered

  2023-09-14

  

  APJ receptor expression is altered in various cardiovascular diseases, and both increases as well as decreases in APJ receptor expression have been reported. A decrease in mRNA and protein levels of APJ receptors was observed in patients with ischemic heart disease or idiopathic dilated cardiomyopat

• We provide here direct evidences that AT receptors

  2023-09-14

  

  We provide here direct evidences that AT1 receptors are active in ADSCs since Ang II induces intracellular Ca mobilization in these cells. Data obtained during the observation of Ca influxes led us to the search for the ADSCs subpopulation constantly expressing AT1 receptor. ADSCs are necessary for

• This suggestion was confirmed by

  2023-09-13

  

  This suggestion was confirmed by immunohistochemical studies in which the immunoreactivity of the enzyme was actually higher at the earlier rather than at the advanced stages of the disease. Importantly, a later study showed that the biochemical signature of 12/15LO enzymatic activation (i.e., 12-HE

• As an alternative to chronic receptor blockade

  2023-09-13

  

  As an alternative to chronic receptor blockade, we have been targeting adenosine kinase (ADK) – an astrocyte-based enzyme that catalyses the phosphorylation of adenosine, as a means to modify β(1,3)-d-glucan synthase adenosinergic signalling (Boison, 2006, Etherington et al., 2009). Up-regulating AD

15731 records 298/1049 page Previous Next First page 上5页 296297298299300 下5页 Last page